Skip to content
Menu

Head-to-head comparison

Ozari Health vs yourEra

Two GLP-1 providers, one scorecard. Both are graded on the same six Desk Score dimensions — here is how they stack up, and which one fits you.

Ranked #145
Ozari Health

Ozari Health is a telehealth weight-loss platform selling physician-prescribed compounded GLP-1 from licensed 503A/503B pharmacies.

$86/mo (promo rate) sema · $125/mo (promo rate) tirz · Verified August 2026

Marked down on: The advertised rates are three-month starter plans for first-time GLP-1 users, billed $257 and $375 up front; month-to-month is $175 and $235

vs
Ranked #18Desk pick
yourEra

A compounded desk that advertises low floors — semaglutide from $79/mo, tirzepatide from $159/mo — with the plan price behind its intake, plus a NAD+ and microdosing menu, across all 50 states.

From $79/mo sema · From $159/mo tirz · Verified August 2026

Marked down on: Compounded only — not FDA-approved and not equivalent to brand Wegovy/Ozempic or Zepbound; availability can tighten as brand shortages resolve

yourEra takes this head-to-head with the higher Desk Score, 85/100 (B) against 73/100 (C) for Ozari Health. Ozari Health still holds its ground where its strengths line up with yours.

Desk Score, dimension by dimension

Same six measured dimensions for both. The red flag marks the stronger side. See the methodology.

Ozari Health

73/100

C

Overall

yourEra

85/100

B

Price transparency

68
90

State access

86
92

Molecule range

66
84

Onboarding speed

70
80

Support responsiveness

74
80

Licensing & trust

79
78

The spec sheet

FieldOzari HealthyourEra
Semaglutide$86/mopromo rate$86/mo (3-mo starter plan, new patients only, compounded)From $79/moFrom $79/mo (a floor — yourera.com attaches no term, dose or billing cycle to it; the plan price is shown only after the intake quiz; compounded)
Tirzepatide$125/mopromo rate$125/mo (3-mo starter plan, new patients only, compounded)From $159/moFrom $159/mo (a floor — yourera.com attaches no term, dose or billing cycle to it; the plan price is shown only after the intake quiz; compounded)
CoverageAll 50 statesAll 50 states
Brand-nameCompounded onlyCompounded only
Oral optionInjectable onlyInjectable only
Best forBudget-focused patients wanting LegitScript-certified compounded GLP-1 from as low as $86/month.Patients drawn by a low advertised floor on both semaglutide and tirzepatide who are willing to complete the intake to learn the plan price, value an add-on NAD+ or microdosing line, and don't need brand-name or oral routes.
Desk Score73/100C85/100B

The verdict

Desk pick — yourEra

yourEra takes this head-to-head with the higher Desk Score, 85/100 (B) against 73/100 (C) for Ozari Health. Ozari Health still holds its ground where its strengths line up with yours.

Choose Ozari Health if…

Budget-focused patients wanting LegitScript-certified compounded GLP-1 from as low as $86/month.

$86/mo (promo rate) sema · $125/mo (promo rate) tirz · All 50 states

Choose yourEra if…

Patients drawn by a low advertised floor on both semaglutide and tirzepatide who are willing to complete the intake to learn the plan price, value an add-on NAD+ or microdosing line, and don't need brand-name or oral routes.

From $79/mo sema · From $159/mo tirz · All 50 states

Assume any provider we list may compensate us — we may earn a referral commission at no extra cost to you, and what we write about a provider reads the same either way. Read full breakdowns: Ozari Health · yourEra.

Also here

CoreAge Rx leads the whole ranking at 94/100

Whichever of these two you lean toward, our #1-rated provider outscores them both. One price at every dose, both molecules, all 50 states. The $99 and $149 figures are 12-month plans paid up front, not a monthly bill.

More head-to-heads

Or see the full comparison hub and the complete ranking.

Pricing and verification reflect each provider's public disclosures at last scoring; the Desk Score is our editorial judgment per the methodology. Prices change — confirm on each provider's own site. Not medical advice; see our disclosure.